Approved indications (U.S. FDA)
In the United States, Emblaveo is approved, together with metronidazole, only for adults 18 years and older who have limited or no alternative treatment options for complicated intra-abdominal infections caused by susceptible Gram-negative organisms such as Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter cloacae complex, Citrobacter freundii complex, and Serratia marcescens.

Off-label and non-U.S. uses
Outside the U.S., Emblaveo is also authorized for hospital-acquired pneumonia, complicated urinary tract infections, and other serious Gram-negative infections in adults with limited options, and U.S. clinicians may consider similar off-label use for difficult multidrug-resistant Gram-negative infections (for example, certain pneumonias, urinary tract infections, or bloodstream infections) based mainly on microbiology data, clinical trials, and foreign approvals rather than large U.S. outcome studies.

Efficacy expectations

• When the bacteria are susceptible and the source of infection (such as an abscess) is controlled, many patients show improvement in fever, pain, and abdominal symptoms within about 48–72 hours.
• Typical treatment courses last 5–14 days, and in clinical trials cure and survival rates for complicated intra-abdominal infection were generally similar to those with meropenem, including in infections caused by resistant Gram-negative organisms.
• Compared with standard broad-spectrum antibiotics, Emblaveo’s main advantage is activity against certain carbapenem-resistant and metallo-beta-lactamase–producing Gram-negative bacteria; when pathogens are fully susceptible to older agents, its effectiveness is comparable rather than superior.

How Emblaveo is given
Emblaveo is prepared and administered by healthcare professionals only, as an intravenous infusion over 3 hours, typically in a hospital setting; for complicated intra-abdominal infections it is always given in combination with intravenous metronidazole to cover anaerobic bacteria.

Typical adult dosing (complicated intra-abdominal infection)

• Normal kidney function (creatinine clearance >50 mL/min): one loading dose of 2.67 g (aztreonam 2 g/avibactam 0.67 g) infused over 3 hours, followed by maintenance doses of 2 g (aztreonam 1.5 g/avibactam 0.5 g) every 6 hours, each infused over 3 hours, for a total treatment duration of 5–14 days depending on clinical response and source control.
• Reduced kidney function: adults with creatinine clearance 30–50 mL/min receive the same loading dose but lower maintenance doses (for example, 1 g every 6 hours), and those with more severe impairment receive smaller doses and/or longer intervals (every 8 or 12 hours); exact adjustments are based on calculated creatinine clearance.
• Hemodialysis: lower doses are used and scheduled after dialysis sessions on dialysis days because both aztreonam and avibactam are removed by hemodialysis.

Special dosing instructions

• The dosing interval is measured from the start of one infusion to the start of the next (for example, every 6 hours), and the drug is not taken by mouth or with food.
• No food or timing restrictions apply for the patient, but it is important to receive every scheduled infusion as arranged by the care team to maintain effective blood levels.

Missed doses and overdose

• If a scheduled dose is missed or an infusion is interrupted, the healthcare team will generally administer the dose as soon as feasible and adjust the schedule; patients should not attempt to alter dosing on their own.
• In suspected overdose, treatment is supportive with close monitoring of kidney function, liver tests, and for neurologic or gastrointestinal symptoms; because both components are dialyzable, hemodialysis can be used to help remove the drug in severe cases, particularly in patients with renal impairment.

Common side effects

• The most common side effects (in more than about 5% of patients) are liver-related lab test abnormalities (elevated transaminases), anemia, diarrhea, low potassium levels, and fever; these usually begin during the course of treatment and are often mild to moderate and reversible after the drug is stopped.
• Other reported effects include nausea, vomiting, abdominal pain, infusion-site reactions (such as pain or phlebitis), rash or flushing, and changes in mental status (confusion or delirium), typically in sicker or older patients.

Serious or rare adverse effects

• Severe allergic reactions, including bronchospasm, anaphylaxis, or sudden widespread rash, hives, or difficulty breathing.
• Serious skin reactions, including toxic epidermal necrolysis, especially in patients with multiple risk factors; new blistering or peeling rash with fever requires immediate medical attention.
• Significant liver injury, signaled by marked increases in liver enzymes, jaundice, dark urine, or severe fatigue and abdominal pain.
• Clostridioides difficile–associated diarrhea, which may present as severe, persistent, or bloody diarrhea during or after treatment.

Warnings and precautions

• Allergy: Contraindicated in patients with known hypersensitivity to aztreonam, avibactam, or components of Emblaveo; caution is advised in those with serious beta-lactam allergies, and any signs of hypersensitivity require stopping the drug.
• Kidney function: Dose reductions and longer dosing intervals are required in moderate to severe renal impairment, and kidney function is monitored during therapy.
• Liver disease: Because liver enzyme elevations are relatively common, patients with underlying liver disease need careful monitoring and possible dose adjustment or discontinuation if injury is suspected.
• Pregnancy and breastfeeding: Human data with aztreonam and avibactam have not identified a clear pattern of birth defects, but information is limited; use in pregnancy or breastfeeding is generally reserved for situations where no better alternatives exist and the expected benefit outweighs potential risks.
• Age limits: Safety and effectiveness have not been established in patients under 18 years of age, and the drug is not approved for pediatric use.

Overall safety profile
In clinical trials, the overall rate and types of adverse events with Emblaveo were broadly similar to comparator regimens such as meropenem, though elevations in liver enzymes were somewhat more frequent and long-term, real-world safety data remain limited, so close monitoring is recommended in high-risk patients.

Reporting side effects and finding safety updates
Suspected side effects can be reported to the manufacturer (AbbVie) or to the U.S. Food and Drug Administration (FDA) through the MedWatch program (online or by calling 1-800-FDA-1088), and up-to-date safety information and communications are available on the FDA and manufacturer websites.

Drug and supplement interactions

• Concomitant use with strong organic anion transporter (OAT) 1 and 3 inhibitors such as probenecid is not recommended, because avibactam is an OAT1/3 substrate and its elimination may be reduced.
• No clinically important interactions have been observed with metronidazole, which is routinely co-administered, and major interactions with most other antibiotics are not expected, but all prescription and over-the-counter medicines should be reviewed by the care team.
• Patients should inform their clinicians about all other drugs, herbal products, and high-dose vitamins or supplements, since new data or individual risk factors may change interaction concerns.

Food, alcohol, and lifestyle factors

• Food does not affect Emblaveo because it is given intravenously rather than taken by mouth.
• Alcohol does not have a direct pharmacokinetic interaction with Emblaveo, but heavy drinking can strain the liver and is generally discouraged during treatment for serious infection.

Conditions and co-medications requiring extra caution

• History of serious allergic reactions to aztreonam or other beta-lactam antibiotics (such as penicillins, cephalosporins, or carbapenems), because cross-reactivity and severe hypersensitivity can occur.
• Moderate to severe kidney impairment, since reduced clearance increases drug exposure and requires dose adjustment and closer monitoring.
• Pre-existing liver disease or elevated liver enzymes, due to the risk of further transaminase elevation or drug-induced liver injury.
• History of Clostridioides difficile infection or significant antibiotic-associated diarrhea, as any broad-spectrum antibiotic can precipitate relapse.

Monitoring needs

• Serum creatinine and estimated creatinine clearance at baseline and periodically during therapy to guide dosing and detect renal toxicity.
• Liver function tests and complete blood counts to monitor for liver injury, anemia, and other blood abnormalities.
• Ongoing clinical observation for allergic reactions, infusion-site problems, new or worsening diarrhea, mental status changes, or other unexpected symptoms so therapy can be adjusted promptly if needed.

Q: What is Emblaveo and what is it used for?
A: Emblaveo is an intravenous combination antibiotic (aztreonam plus avibactam) used with metronidazole to treat complicated intra-abdominal infections in adults who have limited or no other effective treatment options, especially when the infection is caused by certain multidrug-resistant Gram-negative bacteria.

Q: How long will I receive Emblaveo and when should I start to feel better?
A: Most treatment courses last between 5 and 14 days, depending on how severe the infection is and how quickly it responds, and many people begin to feel improvement in fever, pain, and overall well-being within the first 2–3 days once the infected area is adequately drained or surgically managed.

Q: How is Emblaveo different from standard antibiotics?
A: Unlike many older antibiotics, Emblaveo is specifically designed to stay active against some highly resistant Gram-negative bacteria, including those that produce metallo-beta-lactamases and are often resistant to carbapenems, so it is generally reserved for situations where more common antibiotics are unlikely to work.

Q: Can I receive Emblaveo if I am pregnant or breastfeeding?
A: There is limited experience using Emblaveo in pregnant or breastfeeding people, so it is usually considered only when the infection is serious, other options are not suitable, and the expected benefit clearly outweighs the potential but uncertain risks; this decision is made together with your infectious disease and obstetric providers.

Q: Does Emblaveo treat infections like urinary tract infections or pneumonia?
A: In the United States Emblaveo is only approved for complicated intra-abdominal infections, but based on clinical studies and approvals in other regions, specialists may sometimes use it off-label for difficult multidrug-resistant Gram-negative infections in other sites (such as the lungs or urinary tract) when options are very limited and susceptibility is documented.